General Information of Drug (ID: DM9IDUH)

Drug Name
TRX518 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1 [1]
Cross-matching ID
TTD Drug ID
DM9IDUH

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Activation-inducible TNFR family receptor (TNFRSF18) TTG6LA7 TNR18_HUMAN Not Available [2]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Solid tumour/cancer
ICD Disease Classification 2A00-2F9Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Activation-inducible TNFR family receptor (TNFRSF18) DTT TNFRSF18 2.39E-03 -0.54 -0.7
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02628574) Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of Leap Therapeutics.